company background image
RCE

Recce Pharmaceuticals ASX:RCE Stock Report

Last Price

AU$0.78

Market Cap

AU$135.3m

7D

-3.7%

1Y

-25.5%

Updated

25 May, 2022

Data

Company Financials
RCE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

RCE Stock Overview

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom.

Recce Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Recce Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.78
52 Week HighAU$1.38
52 Week LowAU$0.74
Beta1.41
1 Month Change-13.41%
3 Month Change-22.89%
1 Year Change-25.48%
3 Year Change252.27%
5 Year Change307.90%
Change since IPO158.33%

Recent News & Updates

Shareholder Returns

RCEAU PharmaceuticalsAU Market
7D-3.7%-3.7%-1.2%
1Y-25.5%-17.9%-0.009%

Return vs Industry: RCE underperformed the Australian Pharmaceuticals industry which returned -17.9% over the past year.

Return vs Market: RCE underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is RCE's price volatile compared to industry and market?
RCE volatility
RCE Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement9.3%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market4.2%

Stable Share Price: RCE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: RCE's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aJames Grahamhttps://www.recce.com.au

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company’s lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective.

Recce Pharmaceuticals Fundamentals Summary

How do Recce Pharmaceuticals's earnings and revenue compare to its market cap?
RCE fundamental statistics
Market CapAU$135.27m
Earnings (TTM)-AU$8.31m
Revenue (TTM)AU$997.33k

135.7x

P/S Ratio

-16.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RCE income statement (TTM)
RevenueAU$997.33k
Cost of RevenueAU$4.25m
Gross Profit-AU$3.25m
Other ExpensesAU$5.05m
Earnings-AU$8.31m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.048
Gross Margin-326.02%
Net Profit Margin-832.73%
Debt/Equity Ratio0%

How did RCE perform over the long term?

See historical performance and comparison
New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Recce Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


63.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Recce Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Recce Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-41.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RCE is currently unprofitable.

Growing Profit Margin: RCE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RCE is unprofitable, and losses have increased over the past 5 years at a rate of 41.3% per year.

Accelerating Growth: Unable to compare RCE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RCE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).


Return on Equity

High ROE: RCE has a negative Return on Equity (-53.51%), as it is currently unprofitable.


Financial Health

How is Recce Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RCE's short term assets (A$16.3M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: RCE's short term assets (A$16.3M) exceed its long term liabilities (A$128.6K).


Debt to Equity History and Analysis

Debt Level: RCE has more cash than its total debt.

Reducing Debt: RCE's debt to equity ratio has reduced from 0.08% to 0% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RCE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RCE has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 29.7% each year.


Dividend

What is Recce Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RCE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RCE's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RCE has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

James Graham

1.75yrs

Tenure

AU$1,721,922

Compensation

Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD1.22M) is above average for companies of similar size in the Australian market ($USD291.26K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RCE's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: RCE's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Recce Pharmaceuticals Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Recce Pharmaceuticals Ltd
  • Ticker: RCE
  • Exchange: ASX
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$135.267m
  • Shares outstanding: 174.54m
  • Website: https://www.recce.com.au

Location

  • Recce Pharmaceuticals Ltd
  • Aurora Place
  • Level 25
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.